中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(5): 1152-1157

Effect of pretreatment with adenosine monophosphate-activated protein kinase agonist on a rat model of hepatic ischemia-reperfusion injury and related mechanism

DOI: 10.3969/j.issn.1001-5256.2021.05.034
  • 1a.

    Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang 550000, China

  • 1b.

    Department of Information, Guizhou Provincial People's Hospital, Guiyang 550000, China

  • 2.

    The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, China

  • 3.

    Department of Hepatobiliary Surgery, Tongren People's Hospital, Tongren, Guizhou 554300, China

  • 4.

    Department of Hepatobiliary Surgery, Bijie First People's Hospital, Bijie, Guizhou 551700, China

  • Received Date: 2020-11-03
  • Accepted Date: 2020-12-30
  • Published Date: 2021-05-20
    Abstract
  •   Objective  To investigate the effect of pretreatment with adenosine monophosphate-activated protein kinase (AMPK) agonist on rats with hepatic ischemia-reperfusion injury (HIRI) and the possible mechanism.  Methods  A total of 54 healthy specific pathogen-free male Sprague-Dawley rats were randomly and equally divided into 5-aminimidazole-4-formamide nucleotide (AICAR) treatment group (experimental group), ischemia-reperfusion group (control group), and sham-operation group. Samples were collected at 12, 24, and 72 hours after hepatic ischemia-reperfusion surgery to measure the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), tumor necrosis factor-α (TNFα), and interleukin-6 (IL-6) and the level of adenosine triphosphate (ATP) in the liver. HE staining was used to observe liver histological changes; quantitative real-time PCR was used to measure the relative mRNA expression levels of AMPK, mammalian target of rapamycin (mTOR), glucose transporter type 4 (GLUT4), and multidrug resistance-associated protein 2 (MRP2); Western blot was used to measure the protein expression levels of phosphorylated AMPK, phosphorylated mTOR, phosphorylated GLUT4, and MRP2. The repeated-measures analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups.  Results  HE staining showed that the experimental group had milder liver injury than the control group at each time point. At 12, 24, and 72 hours after surgery, the control group had significantly higher serum levels of ALT, AST, TBil, IL-6, and TNFα than the experimental group and the sham-operation group, while the experimental group had significantly higher levels than the sham-operation group (all P < 0.05). At 12, 24, and 72 hours after surgery, the experimental group had a significantly higher level of ATP in liver tissue than the control group and the sham-operation group, and the control group had a significantly lower level than the sham-operation group (all P < 0.05). At 12, 24, and 72 hours after surgery, compared with the control group and the sham-operation group, the experimental group had significantly higher relative mRNA expression levels of AMPK, GLUT4, and MRP2 and protein expression levels of phosphorylated AMPK, phosphorylated GLUT4, and MRP2 (all P < 0.05); compared with the sham-operation group, the control group had significantly higher relative mRNA expression level of AMPK and protein expression level of phosphorylated AMPK, as well as significantly lower relative mRNA expression levels of GLUT4 and MRP2 and protein expression levels of phosphorylated GLUT4 and MRP2 (all P < 0.05). The experimental group had significantly lower relative mRNA expression level of mTOR and protein expression level of phosphorylated mTOR than the control group and the sham-o peration group (all P < 0.05), and compared with the sham-operation group, the control group had significantly higher relative mRNA expression level of mTOR and protein expression level of phosphorylated mTOR (both P < 0.05).  Conclusion  AICAR pretreatment can activate the AMPK signaling pathway, improve energy metabolism pathway, alleviate liver inflammation, and thus reduce the severity of HIRI.

     

    • FullText(HTML)
  • loading
    • References(13)
  • [1]
    CHEN Z, ZHUO R, ZHAO Y, et al. Oleoylethanolamide stabilizes atherosclerotic plaque through regulating macrophage polarization via AMPK-PPARα pathway[J]. Biochem Biophys Res Commun, 2020, 524(2): 308-316. DOI: 10.1016/j.bbrc.2020.01.103.
    [2]
    HUANG L, DAI K, CHEN M, et al. The AMPK agonist PT1 and mTOR inhibitor 3HOI-BA-01 protect cardiomyocytes after ischemia through induction of autophagy[J]. J Cardiovasc Pharmacol Ther, 2016, 21(1): 70-81. DOI: 10.1177/1074248415581177.
    [3]
    LI L, XIAO L, HOU Y, et al. Sestrin2 silencing exacerbates cerebral ischemia/reperfusion injury by decreasing mitochondrial biogenesis through the AMPK/PGC-1α pathway in rats[J]. Sci Rep, 2016, 6: 30272. DOI: 10.1038/srep30272.
    [4]
    PU T, LIAO XH, SUN H, et al. Augmenter of liver regeneration regulates autophagy in renal ischemia-reperfusion injury via the AMPK/mTOR pathway[J]. Apoptosis, 2017, 22(7): 955-969. DOI: 10.1007/s10495-017-1370-6.
    [5]
    LIU H, DONG J, SONG S, et al. Spermidine ameliorates liver ischaemia-reperfusion injury through the regulation of autophagy by the AMPK-mTOR-ULK1 signalling pathway[J]. Biochem Biophys Res Commun, 2019, 519(2): 227-233. DOI: 10.1016/j.bbrc.2019.08.162.
    [6]
    WU MY, YIANG GT, LIAO WT, et al. Current mechanistic concepts in ischemia and reperfusion injury[J]. Cell Physiol Biochem, 2018, 46(4): 1650-1667. DOI: 10.1159/000489241.
    [7]
    YANG LC, ZHANG XY, PAN NB, et al. Effect of rapamycin on the expression of autophagy -related proteins Unc-51 like autophagy activating kinase 1 and microtubule-associated protein 1 light chain 3 in hepatic ischemia-reperfusion injury and its significance[J]. J Clin Hepatol, 2019, 35 (10): 2261-2265. DOI: 10.3969/j.issn.1001-5256.2019.10.026.

    杨龙灿, 张旭阳, 潘宁波, 等. 雷帕霉素在肝脏缺血再灌注损伤中对自噬相关蛋白ULK1、LC3表达的影响[J]. 临床肝胆病杂志, 2019, 35(10): 2261-2265. DOI: 10.3969/j.issn.1001-5256.2019.10.026.
    [8]
    ZHANG XB, ZHAI SP, YUAN W, et al. The role of IL-6, CAT and MPO in hepatic ischemia-reperfusion injury in rats[J]. China Med Herald, 2019, 16(3): 8-10. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201903003.htm

    章小兵, 翟淑萍, 苑伟, 等. IL-6、CAT、MPO在大鼠肝脏缺血再灌注损伤中的作用[J]. 中国医药导报, 2019, 16(3): 8-10. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201903003.htm
    [9]
    LIU H, DONG J, SONG S, et al. Spermidine ameliorates liver ischaemia-reperfusion injury through the regulation of autophagy by the AMPK-mTOR-ULK1 signalling pathway[J]. Biochem Biophys Res Commun, 2019, 519(2): 227-233. DOI: 10.1016/j.bbrc.2019.08.162.
    [10]
    TAJIK KORD M, POURRAJAB F, HEKMATIMOGHADDAM S. Ginger extract increases GLUT-4 Expression preferentially through AMPK than PI3K signalling pathways in C2C12 muscle cells[J]. Diabetes Metab Syndr Obes, 2020, 13: 3231-3238. DOI:10.2147/DMSO. S260224.
    [11]
    ZHANG YQ, DING N, ZENG YF, et al. New progress in roles of nitric oxide during hepatic ischemia reperfusion injury[J]. World J Gastroenterol, 2017, 23(14): 2505-2510. DOI: 10.3748/wjg.v23.i14.2505.
    [12]
    CHEN YG, BIE P, ZHU JY. Expression and significance of MRP2, the major transporter of bilirubin, in rat liver with obstructive jaundice [J]. Third Milit Med Univ, 2004, 26(16): 1429-1431. DOI:10.3321/j.issn: 1000-5404.2004.16.004.

    陈应果, 别平, 祝建勇. 胆红素主要转运子Mrp2在大鼠梗阻性黄疸肝脏中的表达及意义[J]. 第三军医大学学报, 2004, 26(16): 1429-1431. DOI:10.3321/j.issn:1000-5404. 2004.16.004.
    [13]
    ZHANG XY, PAN NB, ZHANG Y, et al. Effects of rapamycin preconditioning on hepatic ischemia-reperfusion injury in Sprague Dawley rats and its related mechanisms [J]. Chin J Hepatobiliary Surg, 2020, 26(5): 378-382. DOI: 10.3760/cma.j.cn113884-20191016-00338.

    张旭阳, 潘宁波, 张玉, 等. 雷帕霉素预处理对Sprague Dawley大鼠肝脏缺血再灌注损伤的影响及相关机制[J]. 中华肝胆外科杂志, 2020, 26(5): 378-382. DOI: 10.3760/cma.j.cn113884-20191016-00338.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (871) PDF downloads(45) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return